SEC Comment Letter 0000000000-23-008660 to RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd.
Date: Aug. 9, 2023 · CIK: 0001553846 · Accession: 0000000000-23-008660
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273709
Letter
United States securities and exchange commission logo August 9, 2023 Dror Ben-Asher Chief Executive Officer and Director RedHill Biopharma Ltd. 8045 Arco Corporate Drive, Suite 200 Raleigh, NC 27617 Re:RedHill Biopharma Ltd. Registration Statement on Form F-3 Filed August 4, 2023 File No. 333-273709 Dear Dror Ben-Asher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jayun Koo, Esq.
Show Raw Text
United States securities and exchange commission logo
August 9, 2023
Dror Ben-Asher
Chief Executive Officer and Director
RedHill Biopharma Ltd.
8045 Arco Corporate Drive, Suite 200
Raleigh, NC 27617
Re:RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed August 4, 2023
File No. 333-273709
Dear Dror Ben-Asher:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jayun Koo, Esq.